Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility
H Albrecht, GL DeNardo, SJ DeNardo - Journal of immunological methods, 2006 - Elsevier
Development of tumor targeting pharmaceuticals on a modular platform is an attractive
paradigm. Design choices for bispecific (anti-tumor and anti-chelate) pretargeting molecules
are increased by the use of scFvs. Because a scFv is monovalent and small in size, its
functional affinity and in vivo residence time can be improved through multimerization. ScFv
multimers can be covalent or non-covalent. In vivo studies indicate that covalent scFv
multimers are preferable. Attachment of scFv modules to scaffolds offers a wide range of …
paradigm. Design choices for bispecific (anti-tumor and anti-chelate) pretargeting molecules
are increased by the use of scFvs. Because a scFv is monovalent and small in size, its
functional affinity and in vivo residence time can be improved through multimerization. ScFv
multimers can be covalent or non-covalent. In vivo studies indicate that covalent scFv
multimers are preferable. Attachment of scFv modules to scaffolds offers a wide range of …